Abstract
Clinical contract research organization Helomics and MDNA Life Sciences, a molecular diagnostics company with a focus on the development of liquid biopsy tests based on the mitochondrial genome, have announced a collaboration centered on the development, validation, and commercialization of MDNA’s Mitomic Technology platform.
7active studio / Getty Images
“This strategic relationship with Helomics will enable us to accelerate product development, clinical validation, and the commercialization of our deep pipeline of novel, best-in-class liquid biopsy tests,” said Chris Mitton, president and CEO of MDNA.
In its initial stages, Helomics will offer MDNA’s Prostate Core Mitomic Test and its liquid biopsy Prostate Mitomic Test in selected U.S. markets through its CLIA-approved clinical laboratory. As part of the ongoing broader development work, MDNA will grant Helomics a license to offer diagnostics tests based on MDNA’s proprietary mitochondrial DNA technology to Helomics clients in the diagnostics, pharmaceutical, and biotechnology industries as part of its menu of services as a contract research organization.
“We anticipate that, by leveraging the core expertise of both companies, many new diagnostic tests will be developed and commercialized that will lead to a better understanding of the uniqueness of a patient’s cancer,” added Gerald J. Vardzel, Jr., Helomics president and CEO.